Novel interaction of apolipoprotein(a) with β-2 glycoprotein I mediated by the kringle IV domain

Blood

Volumn 90, Issue 4, 1997, Pages 1482-1489

  Köchl, Silvano ^a   Fresser, Friedrich ^a   Lobentanz, Eva ^a   Baier, Gottfried ^a   Utermann, Gerd ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; BETA GALACTOSIDASE; BETA2 GLYCOPROTEIN 1; FIBRONECTIN;

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; KRINGLE DOMAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE;

EID: 0242657000     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.4.1482     Document Type: Article

References (58)

1. Utermann G: The mysteries of lipoprotein(a). Science 246:904, 1989
2. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein (a) is homolgous to plasminogen. Nature 300:132, 1987
3. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH: Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87:2153, 1991
4. Koschinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM: Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 29:640, 1990
5. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C: Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 80:458, 1987
6. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G: The apolipoprotein(a) gene: A transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 90:220, 1992
7. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V, Schonitzer D, Utermann G: Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16:713, 1996
8. Utermann G: Lipoprotein(a), in Scriver ChR, Beaudet AL, Sly WS, Valle D (eds): The metabolic and molecular bases of inherited disease. New York, NY, McGraw Hill, 1995, p 1887
9. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF: A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339:301, 1989
10. Miles LA, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, Curtiss LK, Levin EG, Hoover-Plow JL, Plow EF: Interaction of Lp(a) with plasminogen binding sites on cells. Thromb Haemost 73:458, 1995
11. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC: Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1:256, 1995
12. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC: Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370:460, 1994
13. Harpel P, Gordon B, Parker T: Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 86:3847, 1989
14. Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E: Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator: In vitro studies in a plasma milieu. Arteriosclerosis 11:629, 1991
15. Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E: Apolipoprotein(a) and plasminogen interactions with fibrin: A study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 31:6333, 1992
16. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 339:303, 1989
17. Gonzales-Gronow M, Edelberg J, Pizzo S: Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein (a) compete for the same site. Biochemistry 28:2374, 1989
18. Salonen E-M, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C: Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 8:4035, 1989
19. Fields S, Song OK: A novel genetic system to detect protein-protein interactions. Nature 340:245, 1989
20. Bartel P, Chien CT, Sternglanz R, Fields S: Elimination of false positives that arise in using the two-hybrid system. Biotechniques 14:920, 1993
21. Polz E, Kostner GM: The binding of β2-glycoprotein I to human serum lipoproteins: Distribution among density factors. FEBS Lett 102:183, 1979
22. Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD, Fong KJ, Meer K, Patthy L: The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J Biol Chem 270:24004, 1995
23. Loscalzo J, Weinfeld M, Fless GM, Scanu AM: Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 10:240, 1990
24. Edelberg JM, Gonzalez-Gronow M, Pizzo SV: Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 57:155, 1990
25. Kluft C, Jie AFH, Los P, De Wit E, Havekes L: Functional analogy between lipoprotein(a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin. Biochem Biophys Res Commun 161:427, 1989
26. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL: Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 266:2459, 1991
27. Miles LA, Plow EF: Lp(a): An interloper into the fibrinolytic system? Thromb Haemost 63:331, 1990
28. Kojima S, Harpel PC, Rifkin DB: Lipoprotein (a) inhibits the generation of transforming growth factor β: An endogenous inhibitor of smooth muscle cell migration. J Cell Biol 113:1439, 1991
29. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM: Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260:1655, 1993
30. Brown MS, Goldstein JL: Teaching old dogmas new tricks. Nature 83:113, 1987
31. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579, 1989
32. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM: Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360:670, 1992
33. Van der Hoek YY, Sangrar W, Côté GP, Kastelein JJP, Koschinsky ML: Binding of recombinant apolipoprotein(a) to extra-cellular matrix proteins. Arterioscler Thromb 14:1792, 1994
34. Lee NS, Brewer HBJ, Osborne JCJ: Beta 2-glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H. J Biol Chem 258:4765, 1983
35. Schultze HE, Heide K, Haupt H: Über ein bisher unbekanntes niedermolekuläres b2-Globulin des Humanserums. Naturwissenschaften 48:719, 1961
36. Reid KBM, Day AJ: Structure-function relationships of the complement components. Immunol Today 10:177, 1989
37. Steinkasserer A, Cockburn DJ, Black DM, Boyd Y, Solomon E, Sim RB: Assignment of apolipoprotein H (APOH: beta-2-glycoprotein I) to human chromosome 17q23-qter: determination of the major expression site. Cytogenet Cell Genet 60:31, 1992
38. Kristensen T, D'Eustachio P, Ogata RT, Chung LP, Reid KB, Tack BF: The superfamily of C3b/C4b-binding proteins. Fed Proc 46:2463, 1987
39. Seifert PS, Roth I, Zioncheck TF: The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation. Atherosclerosis 93:209, 1992
40. Nakaya Y, Schaefer EJ, Brewer HB: Activation of human post heparin lipoprotein lipase by apolipoprotein H (β-2 glycoprotein I). Biochem Biophys Res Commun 95:1168, 1980
41. Wurm H, Beubler E, Polze E, Holasek A, Kostner G: Studies on the possible function of β2-glycoprotein I: Influence in the triglyceride metabolism in rat. Metabolism 32:484, 1982
42. Kamboh MI, Ferrel RE: Apo H polymorphism and its role in lipid metabolism. Adv Lipid Res 1:9, 1991
43. Schousboe IT: Beta 2-glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66:1086, 1985
44. Nimpf J, Wurm H, Kostner GM: Beta 2-glycoprotein-I (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63:109, 1987
45. Nimpf J, Bevers EM, Bormans PH, Till U, Wurm H, Kostner GM, Zwaal RT: Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein I. Biochim Biophys Acta 884:142, 1986
46. Mehdi H, Kaplan MJ, Anlar FY, Yang X, Bayer R, Sutherland K, Peeples ME: Hepatitis B virus surface antigen binds to apolipoprotein H. J Virol 68:2415, 1994
47. Neurath AR, Strick N: The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV. Virology 204:475, 1994
48. Chonn A, Semple SC, Cullis PR: Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem 270:25845, 1995
49. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM: Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 87:767, 1991
50. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Antiphospholipid antibodys are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: Beta 2-glycoprotein-I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120, 1990
51. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJ, Barbui T, Zwaal RF, Bevers EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544, 1990
52. Hunt JE, Simpson RJ, Krilis SA: Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 90:2141, 1993
53. Viard JP, Amoura Z, Bach JF: Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93:181, 1992
54. Fort JG, Cowchock FS, Abruzzo JL, Smith JB: Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum 30:752, 1987
55. Hughes GR, Harris NN, Gharavi AE: The anticardiolipin syndrome. J Rheumatol 13:486, 1986
56. Yamazaki M, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Ikeda T, Matsuda T: Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 71:424, 1994
57. Borba EF, Santos RD, Bonfa E, Vinagre CG, Pileggi FJC, Cossermelli W, Maranhao RC: Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol 21:220, 1994
58. Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M: Lipoprotein(a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemost 74:799, 1995